RxDoctor Payments Data

Michael Waligora, MD

Cardiovascular Disease · Glenview, ILNPI 1699742163

Payments from drug & device makers

$1,728in general payments, 2019–2025

Across 68 payments — averaging $25.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$332
  • AstraZeneca$183
  • Boehringer Ingelheim$160
  • Novo Nordisk$124
  • Amgen$102
  • Bridgebio Pharma, Inc.$90
  • plus $736 from 14 others

What the payments were for

  • Food & beverage$1,728100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,728 in reported general payments places this provider in the 45th percentile of 932 cardiovascular disease providers in Illinois.

See all cardiovascular disease providers in Illinois

Medicare billing

Part B allowed, 2024
$216,398
Medicare patients
2,683
Services billed
5,102

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban379$543,932
FarxigaDapagliflozin Propanediol50$72,353
XareltoRivaroxaban38$50,668
JardianceEmpagliflozin23$37,015
Repatha SureclickEvolocumab38$30,907
VascepaIcosapent Ethyl20$21,183
EntrestoSacubitril/Valsartan11$18,708
Repatha SyringeEvolocumab16$15,743
OzempicSemaglutide14$11,097
Icosapent Ethyl18$10,670
Atorvastatin Calcium609$7,163
Praluent PenAlirocumab11$6,966
Metoprolol Succinate343$6,519
Ezetimibe235$4,719
Carvedilol393$4,166

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$30$543,932379 claims
AstraZenecaFarxiga$183$72,35350 claims
Johnson & JohnsonXarelto$71$50,66838 claims
Boehringer IngelheimJardiance$160$37,01523 claims
NovartisEntresto$332$18,70811 claims
Novo NordiskOzempic$124$11,09714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 932 cardiovascular disease providers in Illinois.

Other cardiovascular disease in Glenview

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →